Antidepressants Step Therapy Program Summary
Customize your policy alerts
Sign up for all prime_therapeutics policy alerts
Know when prime_therapeutics releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and step therapy approval for targeted antidepressant agents and specified duloxetine products under the Boeing commercial formulary. Coverage generally requires use, inadequate response, intolerance, contraindication, or another documented medical-necessity exception involving generic antidepressant or other prerequisite agents.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.